SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-24-000111
Filing Date
2024-08-08
Accepted
2024-08-08 16:34:10
Documents
84
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvnc-20240630.htm   iXBRL 10-Q 1483256
2 EX-31.1 rvncq224exhibit311.htm EX-31.1 8686
3 EX-31.2 rvncq224exhibit312.htm EX-31.2 8684
4 EX-32.1 rvncq224exhibit321.htm EX-32.1 5096
5 EX-32.2 rvncq224exhibit322.htm EX-32.2 5134
  Complete submission text file 0001479290-24-000111.txt   8525487

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240630.xsd EX-101.SCH 58837
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20240630_cal.xml EX-101.CAL 112120
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20240630_def.xml EX-101.DEF 294405
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240630_lab.xml EX-101.LAB 717374
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240630_pre.xml EX-101.PRE 516857
87 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240630_htm.xml XML 1342355
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 241189042
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)